UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): February 14, 2018
INSMED INCORPORATED
(Exact name of registrant as specified in its charter)
|
Virginia |
|
000-30739 |
|
54-1972729 |
|
(State or other jurisdiction of |
|
(Commission File Number) |
|
(I.R.S. Employer Identification |
|
10 Finderne Avenue, Building 10 |
|
08807 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (908) 977-9900
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
ITEM 7.01 — Regulation FD Disclosure.
As previously announced, Insmed Incorporated (the “Company”) will present at the Leerink Partners 7th Annual Global Healthcare Conference in New York on Wednesday, February 14, 2018 and a live webcast of the event will be available through the investor relations section of the Company’s website. The slide presentation to be used by the Company during the conference is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
ITEM 9.01 - Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit |
|
Description |
|
99.1 |
|
Insmed Incorporated Investor Presentation, dated February 14, 2018. |
EXHIBIT INDEX
|
Exhibit |
|
Description |
|
99.1 |
|
Insmed Incorporated Investor Presentation, dated February 14, 2018. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: February 14, 2018 |
INSMED INCORPORATED | |
|
|
|
|
|
|
By: |
/s/ Christine Pellizzari |
|
|
Name: |
Christine Pellizzari |
|
|
Title: |
Chief Legal Officer |